France
AQEMIA, founded in 2019, is a cutting-edge company at the intersection of AI and biotechnology, focusing on drug discovery through the use of quantum-inspired physics and generative AI. The company specializes in creating novel medicines to address significant diseases, particularly in the oncology space, and is known for seeking solutions beyond the capabilities of traditional R&D.
Headquartered in France, with additional operations in London, AQEMIA is part of the French Tech 120 program, highlighting its potential for global impact. The company's innovative platform has already led to several discovery successes and collaborations with top pharmaceutical firms, moving promising candidates toward in vivo optimization.
In its most recent financial milestone, AQEMIA secured a $7.40M grant investment led by France 2030 on April 1, 2025. This boost underscores investor confidence in AQEMIA's pioneering approach in the life sciences sector and its ongoing growth trajectory.
